Belimumab (Benlysta®) is a human monoclonal antibody that specifically recognizes and blocks the biological activity of B-lymphocyte stimulator. Elevated levels of BLyS prolong the survival of B lymphocytes (B cells) which can contribute to the production of autoantibodies - antibodies that target the body's own tissues. Studies have shown that belimumab can reduce autoantibody levels and help control autoimmune disease activity.
Belimumab (Benlysta) is administered either intravenously or subcutaneously, in the treatment of adult individuals with active, auto-antibody positive systemic lupus erythematosus who are receiving standard therapy.
Belimumab (Benlysta) intravenous infusion may be covered under the medical benefits; please refer to pharmacy policies for coverage of Belimumab (Benlysta) self-administered subcutaneous injection.